ABSTRACT
INTRODUCTION
Lipids are essential and highly abundant components of all organisms. They serve as the main building blocks of the membranes that surround and compartmentalize cells, as a store for energy and reduction power, and as post-translational modifications that regulate the localization and function of a large number of proteins. Lipids have also emerged as important pathogenesis factors in a variety of infectious diseases. The ability to synthesize or salvage simple components like fatty acids and isoprenoids and assemble them into more complex molecules is critical for the growth and development of the pathogen, and required for its ability to colonize the host and to cause disease. Here we will focus on the fatty acid metabolism of apicomplexans, a group of unicellular eukaryotes that have adapted to an obligate intracellular life-style. Infections with apicomplexan parasites are the cause of several important human diseases (malaria, toxoplasmosis and cryptosporidiosis) affecting literally millions of people around the globe. Control efforts for these diseases face an uphill battle as effective vaccines are lacking for any of these parasites, and drug treatment is not fully effective
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(cryptosporidiosis), limited to the acute stage (toxoplasmosis), or constantly threatened by emerging drug resistance (malaria). The completion of full genome sequencing efforts for a considerable number of apicomplexans has reinvigorated the search for targets of novel therapeutics. Lipid and fatty acid metabolism has emerged to be at the heart of several intensely studied areas of apicomplexan biology, including parasite adaptation to different hosts, host-parasite interaction at the cellular level, and the identification of divergent pathogen-specific targets for anti-parasitic drug therapy. Here we will provide an overview over the surprisingly diverse mechanisms of fatty acid synthesis and uptake used by the members of this important group of pathogens.
Make it I: The apicoplast type II fatty acid synthesis pathway (FASII)
Apicomplexans were thought to lack the ability to synthesize fatty acids de novo and to entirely depend on salvaging fatty acids and several more complex lipids from their hosts (71) . Initially, radioisotope experiments designed to detect de novo synthesis did not produce detectable labeling, while evidence for fatty acid and lipid uptake from the infected host cell was abundant (see below for detail). This model came into question with the discovery of the apicoplast, a chloroplast-like organelle that is likely the descendent of an endosymbiotic red alga (33, 38, 76) . Plant and algal plastids are not only the home of photosynthesis but also harbor several other key biosynthetic pathways.
Genomic and experimental analyses have identified pathways for the synthesis of fatty acids (73) , isoprenoids (27), and heme (55) in the apicoplast. Fatty acid synthesis in the apicoplast depends on a prokaryotic type II system, previously characterized in bacteria and chloroplasts. A complete set of genes encoding the components of FASII have been (51, 73) , Toxoplasma gondii (73) and Eimeria tenella (15) (see Fig. 1 for a comparative overview of apicomplexan genes associated with fatty acid metabolism). Phylogenetic analyses strongly support the chloroplast origin of these genes, and apicoplast targeting has been experimentally demonstrated for several of the encoded proteins (73) .
A C C E P T E D identified in Plasmodium falciparum
The core of the FASII system is acyl carrier protein (ACP, see Mammalian cells lack FASII and instead rely on FASI, a gigantic protein that carries ACP as well as the various enzymatic activities that act on the growing chain described above on a single polypeptide. FASI and FASII differ in structure, kinetics and susceptibility to several inhibitors, making the apicoplast FASII an attractive target for the development of parasite specific drugs. Indeed, several lines of evidence indicate that the apicoplast FASII pathway is essential for parasite viability. Conditional knock-out experiments using a tetracyline-regulated promoter in T. gondii have demonstrated that expression of apicoplast ACP is essential for parasite survival in tissue culture (37).
Furthermore, mice infected with a lethal dose of mutant parasites can be cured by
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tetracyline-mediated FASII suppression. Consistently, pharmacological studies using drugs that preferentially inhibit FASII enzymes over FASI (e.g. triclosan or thiolactomycin) have found strong growth inhibition in Plasmodium and Toxoplasma (39, 49, 63) . The interaction of Pf and Tg FabI with triclosan has been studied in considerable detail. Kinetic and structural data support FabI as the target enzyme in these parasites and have identified residues critical to inhibitor binding (30, 46, 49) . Based on these data, several groups have embarked on structure-and screening-based programs to identify novel inhibitors of PfFabI with increased potency and specificity (8, 48) . Recently FabB/F has been characterized and confirmed as the target of thiolactomycin, a FAS II specific inhibitor with demonstrated efficacy against T. gondii and P. falciparum (28, 37, 74, 75) . Structural and kinetic information is now also available for recombinant Pf FabG (75) and FabZ (56, 64) . Overall, it is clear now that apicoplast FASII is essential and a validated drug target. The enzymology of the pathway is well-established and excellent reagents are available for compound screening and structure-activity relationship analysis ((21, 62) provide in depth reviews of current drug development efforts focused on the Plasmodium FASII pathway).
While the apicoplast FASII pathway is clearly essential, the function of FASII and its integration into the overall parasite metabolism is less clear. The chloroplast is the main source of fatty acids in the plant cell, and bulk fatty acid production is therefore the obvious first hypothesis. In P. falciparum-infected blood cultures, Surolia and colleagues demonstrated incorporation of [
14 C]-acetate into fatty acids, preferentially resulting in the production of C:10-C:14. Importantly this incorporation is sensitive to triclosan inhibition A C C E P T E D (63 (16, 17) , and one could speculate that metabolites might be exchanged between plastid and mitochondrion, which are closely apposed through much of the intracellular development of the parasites (69, 70) . However, the finding that Theileria, an apicomplexan that lacks the FASII pathway, equally lacks PDH could argue against this model and suggest that the criticial role of PDH is likely to provide acetyl-CoA for fatty acid synthesis (19) . It is important to bear in mind that the lack of FASII dependent radiolabeling in T. gondii does not exclude the possibility that FASII produces bulk fatty acids. It is e.g. possible that the Toxoplasma and Plasmodium apicoplasts differ in their ability to import acetate thus precluding labeling. Lastly, one might consider apicoplast specific roles for the FASII pathway. Supporting such a view is the observation that FASII inhibition results in pronounced apicoplast biogenesis defects in T. gondii (37).
Make it II: Alternative routes of fatty acid synthesis through FASI and PKS-like enzymes
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As described above, acetate incorporation into fatty acids is independent of the FASII pathway in T. gondii. What other system could be responsible for this activity? An alternative pathway has been described in the related apicomplexan Cryptosporidium parvum. Cryptosporidium lacks both the apicoplast organelle and the associated FASII pathway, and instead its genome encodes a very large (~900 kDa) FASI-like protein (1, 83, 84). This enzyme contains four ACP domains and is organized into a loading unit, three elongation and reduction modules, and a putative terminating reductase domain Looking at the distribution of FASI and PKS genes in apicomplexa it appears that these genes are linked and restricted to species that form oocysts that are shed into the environment (Cryptosporidium, Toxoplasma and Eimeria). One might speculate that the products of FASI and PKS serve a function in theses life cycle stages, e.g. as a component of the impenetrable and highly resilient oocyst wall, or as a factor required for development within the vertebrate intestinal epithelium.
Make it III: ER-resident fatty acid synthesis/elongation through the ELO-system
A third avenue for fatty acid synthesis is represented by the fatty acid elongation system (ELO). The enzymatic steps involved in the ELO process are similar to FASI and II but the growing chain is held by CoA instead of ACP. As implied by the name, the main role of this system, which is found in the endoplasmic reticulum of most eukaryotes, is to sequentially elongate fatty acids to supply the demand of long-chain fatty acids for the production of phospholipids (see (36) for an in depth review). An analogous system of divergent phylogenetic origin is responsible for the synthesis of wax precursors in plants (68) . Recent elegant work in Trypanosoma brucei (the causative agent of sleeping sickness and Nagana) has demonstrated that the ELO system in this organism has been adapted to the de novo synthesis of fatty acids (23, 35) . While the three yeast ELOs add 
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The precursor supply chain for fatty acid synthesis
Fatty acid synthesis requires acetyl-CoA, malonyl-CoA, energy and reduction power in the form of ATP and NAD(P)H. It has been proposed that cytoplasmic glycolysis supplies phosphoenolpyruvate which is imported into the plastid and subsequently metabolized to acetyl-CoA ((51), schematically outlined in Fig. 1 
related open question is the source of malonyl-CoA for the elongase system. In Plasmodium, the single ACCase is likely localized to the apicoplast, suggesting that this is the only compartment where malonyl-CoA production can occur. Malonyl-CoA might be exported from the apicoplast to the cytoplasm or there may be an alternative ACCaseindependent source yet to be characterized (this question remains equally unanswered in T. brucei, where the sole ACCase is likely localized to the mitochondrion (35)).
Take it: Fatty acid salvage from the host cell
There is strong evidence for the uptake of fatty acids in essentially all apicomplexans that have been analyzed. Incubation of T. gondii or P. falciparum with radio-or fluorescence labeled fatty acids results in incorporation of label within the parasite (7, 20, 66) . In T.
gondii, such incorporation occurs in free tachyzoites as well as in infected host cells, and has also been observed for a variety of phospholipids. Both parasites convert fatty acids taken up from the host to triacylglycerides using an ER resident acyl-CoA:diacylglycerol acyltransferase, with these triglycerides being subsequently stored in lipid bodies (7, 50, 72) .
What are the cellular mechanisms of fatty acid and more generally lipid salvage?
Considering this question, it is important to note that different apicomplexan species inhabit host cells with different architecture and metabolic capability. It is therefore conceivable that varied and divergent mechanisms exist (see Fig. 2 In Toxoplasma it has been long noticed that the PV recruits and establishes intimate contact with the host cell's endoplasmic reticulum and mitochondria (58, 59 ) and similar findings have been recently reported for the hepatocyte stage of Plasmodium (3). Such intimate association has been shown to be crucial for lipid uptake in a variety of bacterial pathogens (54) . A second such interaction with the secretory pathway of the host cell has been described for the host cell endosome/lysosome. This model is based on extensive studies of sterol uptake in T. gondii (for which the parasites lack biosynthetic pathways).
Intracellular parasites readily take up fluorescently labeled sterols supplied in the medium. In experiments taking advantage of mutant host cells, Coppens and colleagues concluded that the parasite intercepts the endosome/lysosome pathway to secure lowdensity lipoprotein-derived cholesterol (9, 11) . In more recent work these authors identify microtubular projections from the host cell cytoplasm into the space of the PV. Host cell endocytic structures which travel along these microtubles are trapped within the vaculoar space, with the parasite protein GRA7 mediating this sequestration process (10) . This pathway could be a conduit not only for cholesterol but also for other lipids. The
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lysosome trapping model at least partially contradicts the previously held (and experimentally supported) view that the PV is fusion incompetent and hence isolated from the host cell secretory and endosomal pathway (26, 42, 43) . Further studies are needed to unify these two models.
The most recent model for fatty acid uptake emerged from expression profiling along the Plasmodium life cycle. This work has identified numerous genes that are upregulated in the infective sporozoite (UIS) when compared to blood cell stages (29). Gene targeting experiments have validated this finding and demonstrated that, while dispensable in the erythrocyte, they are essential for development in the hepatocyte earlier in infection (44, 45) . Infection with these mutants resulted in strong protection to subsequent challenge, a fact that has rekindled the interest in the development of a live attenuated malaria vaccine. One of these genes, UIS3, encodes a type I transmembrane protein that is secreted and inserted into the PV membrane in infected hepatocytes so that its C-terminal domain is exposed to the host cell's cytoplasm (41) . A yeast two-hybrid screen performed using the exposed domain as bait found strong interaction between UIS3 and liver fatty acid binding protein, a finding that was confirmed by co-immunoprecipitation from infected cells. This interaction is critical for the parasite as removing either partner by gene targeting (UIS3) or RNAi (L-FABP) blocks development of the liver cell schizont (41, 44, 45) . Based on these observations it is likely that UIS3 promotes fatty acid uptake from the host cell. Recruitment of fatty acid loaded L-FABP to the PV membrane could increase the availability of fatty acids to passive or active transport mechanisms. How
this exactly occurs remains to be established, but the UIS gene catalog provides an exciting list of candidate genes to dissect this important process.
What is the reason for the surprising diversity of the fatty acid metabolism across the phylum?
Genomic analysis leads us to a stark reversal of the initial assumption of lack of fatty acid synthesis in apicomplexans. As discussed above members of this phylum engage three independent fatty acid synthesis machineries (FASI, FASII and ELO). A second surprise is the diversity of the fatty acid metabolism in different species of the phylum (see table 1 and Fig. 3) . Theileria is the apicomplexan fatty acid minimalist. This parasite not only lacks de novo synthesis capabilities but is also unable to elongate fatty acids (19) .
Consistent with the lack of fatty acid synthesis, Theileria also lacks the enzymes to produce malonyl-CoA, acetyl-CoA (through PDH -there is an acetyl-CoA synthase likely used for other purposes) and ACP-holoenzyme synthase (see table 1 ). It has retained a single fatty acid binding protein and several acyl-CoA synthases, pointing to their potential role in salvage. Why can Theileria thrive without pathways essential to other apicomplexans? One obvious difference is the cytoplasmic niche occupied by this parasite (57) . The absence of a PV allows for a more intimate contact with the host cell and might facilitate uptake and/or manipulation of the host pathways to suit the needs of the parasite. Cryptosporidium is another apicomplexan known for its stripped down biosynthetic metabolism -the apicoplast and its metabolic capabilities, including a FASII system have been lost in this organism (1, 83). However, the parasite has maintained a FASI system (albeit for elongation and not de novo synthesis), a PKS, and a single ELO.
Plasmodium uses an apicoplast FASII for de novo synthesis of fatty acids and this synthesis is essential to parasite survival. Nonetheless, this parasite also engages in fatty acid uptake and elongation. The Plasmodium genome encodes a host of acyl-CoA synthases and binding proteins that appear to be under selective pressure (4) . In the hepatocyte, the uptake system is further enhanced by a protein that recruits host fatty acid binding proteins to the PV (this protein appears unique to Plasmodium). Lastly, The diversity of the pathways throughout the phylum might be taken as an indication that the availability of (the right) fatty acids is an essential determinant to successful host adaptation for apicomplexans. Parasites inhabiting metabolically largely inactive environments like the red blood cell might depend more heavily on de novo synthesis, while those having ready access to host fatty acids lean towards uptake. It also appears that different ways to acquire fatty acids have evolved in parallel in different species, and much remains to be learned about the mechanistic detail of these processes. While the ability to comparatively mine the genomes of a variety apicomplexans has led to the discovery of numerous pathways, the precise biological and metabolic function of each pathway remains largely unexplored. Also, our understanding of the cellular compartmentalization of the pathways and their precursor supply chains is rudimentary.
The example of Plasmodium suggests that dramatic metabolic changes occur along the life-cycle progression and that not all enzymes encoded in the genome might be used in the most widely studied culture models. However, strong post-genomic tools like expression profiling, proteomics and metabolomics are now available to the field to tackle these questions. Combining these tools with our increased ability to genetically modify apicomplexans (currently limited to Toxoplasma, Plasmodium and Eimeria)
should permit the dissection of what is emerging as a complex, yet critically important component of host-parasite interaction. Importantly, fatty acid synthesis and uptake are essential to parasite growth and pathogenesis, and ongoing work on the Plasmodium and Toxoplasma FASII pathway demonstrates that the fatty acid metabolism holds promise for parasite specific drug targets. Additional targets might emerge from a more detailed understanding of uptake pathways.
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